secwatch / observer
8-K filed December 14, 2022, 6:59 PM ET ticker PM CIK 0001413329
leadership confidence high sentiment neutral materiality 0.40

Philip Morris appoints Jorge Insuasty President of Vectura Fertin Pharma; adjusts de Wilde's compensation

Philip Morris International Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Frederic de Wilde

President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region
PM · Philip Morris International Inc.
Filed
December 14, 2022, 6:59 PM ET
Frederic de Wilde, currently President, European Union Region, will be appointed President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region.
Role change

Jorge Insuasty

President, Vectura Fertin Pharma
PM · Philip Morris International Inc.
Effective
2023-01-01
Filed
December 14, 2022, 6:59 PM ET
On December 8, 2022, the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company”) approved the appointment of Jorge Insuasty as the full-time President, Vectura Fertin Pharma, effective January 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frederic de Wilde was appointed as President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region at Philip Morris International Inc..

Action
appointed
Role
President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region
Exact text from the filing
Frederic de Wilde, currently President, European Union Region, will be appointed President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jorge Insuasty was appointed as President, Vectura Fertin Pharma at Philip Morris International Inc..

Action
appointed
Role
President, Vectura Fertin Pharma
Exact text from the filing
On December 8, 2022, the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company”) approved the appointment of Jorge Insuasty as the full-time President, Vectura Fertin Pharma, effective January 1, 2023.
View on SEC.gov

Philip Morris International Inc. filing history →

Source: SEC EDGAR
accession 0001413329-22-000137
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.